The disposition of recombinant human erythropoietin (EPOCH) after subcutaneous administration. (3). The disposition of 125I-EPOCH after multiple subcutaneous administration in rats.
スポンサーリンク
概要
- 論文の詳細を見る
We studied the absorption, distribution and excretion of radioactivity after 4 times multiple subcutaneous administrations of <SUP>125</SUP>I-EPOCH at an interval of 48 hours.<BR> 1. Plasma levels of immunoreactive radioactivity at 10h and 48h following each multiple administration did not change during the experimental period. There were no pronounced differences in pharmacokinetics between first and fourth administration.<BR> 2. The levels of radioactivity in spleen and bone marrow after multiple administration were slightly higher than those after administration of a single dose. Those in other tissues except thyroid gland, were similar to those after administration of a single dose. The remained radioactivity in the injection site at 10h after multiple administration was 33.65%, which was similar to that of single administration.<BR> 3. Until 96h after final administration of <SUP>125</SUP>I-EPOCH, urinary excretions of total. the TCA-precipitable and the immunoreactive radioactivity were 76.43%, 0.97%, 0.49%, respectively. Fecal excretion of total radioactivity was 3.83%, until 96h after final administration.
- 日本薬物動態学会の論文
日本薬物動態学会 | 論文
- COMPETITIVE DISPLACEMENT OF SERUM PROTEIN BINDING TO REGULATE PHARMACOKINETICS OF A CEREBRAL BLOOD FLOW RADIOPHARMACEUTICAL
- Studies on the Metabolic Fate of Felodipine. (IV). Identification of New Metabolites of Felodipine in Rat.
- Metabolic Fate of Pergolide Mesylate. (2): Absorption, Distribution, Excretion of 14C-Pergolide Mesylate in Rats after Repeated Administration.
- Studies on the Metabolic Fate of 3H-TJN-101. (III): Absorption, Distribution and Excretion after Multiple Oral Administration to Rats.
- Studies on the Pharmacokinetics of Perindopril Erbumine in Rats. (1): Plasma Level Profile, Distribution, Metabolism and Excretion after Single Oral Administration.